These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 25178575

  • 1. Treatment of primary Sjögren syndrome with rituximab. In response.
    Saraux A, Nowak E, Devauchelle-Pensec V.
    Ann Intern Med; 2014 Sep 02; 161(5):377-8. PubMed ID: 25178575
    [No Abstract] [Full Text] [Related]

  • 2. Treatment of primary Sjögren syndrome with rituximab.
    Faustman DL, Vivino FB, Carsons SE.
    Ann Intern Med; 2014 Sep 02; 161(5):376-7. PubMed ID: 25178574
    [No Abstract] [Full Text] [Related]

  • 3. Does rituximab help patients with primary Sjögren syndrome?
    Ann Intern Med; 2014 Feb 18; 160(4):I-11. PubMed ID: 24727838
    [No Abstract] [Full Text] [Related]

  • 4. Summaries for patients. Does rituximab help patients with primary Sjögren syndrome?
    Ann Intern Med; 2014 Feb 18; 160(4):I-11. PubMed ID: 25006621
    [No Abstract] [Full Text] [Related]

  • 5. [B-cell depletion and primary Sjögren's syndrome: is there a role for rituximab?].
    Atzeni F, Sarzi-Puttini P.
    Reumatismo; 2010 Feb 18; 62(2):87-8. PubMed ID: 20657883
    [No Abstract] [Full Text] [Related]

  • 6. First report of improvement of coeliac disease in a patient with Sjögren's syndrome treated with rituximab.
    Nikiphorou E, Hall FC.
    Rheumatology (Oxford); 2014 Oct 18; 53(10):1906-7. PubMed ID: 24729401
    [No Abstract] [Full Text] [Related]

  • 7. Treatment of primary Sjögren syndrome with rituximab: a randomized trial.
    Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, Le Guern V, Sibilia J, Gottenberg JE, Chiche L, Hachulla E, Hatron PY, Goeb V, Hayem G, Morel J, Zarnitsky C, Dubost JJ, Pers JO, Nowak E, Saraux A.
    Ann Intern Med; 2014 Feb 18; 160(4):233-42. PubMed ID: 24727841
    [Abstract] [Full Text] [Related]

  • 8. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial.
    Moerman RV, Arends S, Meiners PM, Brouwer E, Spijkervet FK, Kroese FG, Vissink A, Bootsma H.
    Ann Rheum Dis; 2014 Feb 18; 73(2):472-4. PubMed ID: 23940214
    [No Abstract] [Full Text] [Related]

  • 9. Complete remission of protein-losing gastroenteropathy associated with Sjögren's syndrome by B cell-targeted therapy with rituximab.
    Uraoka Y, Tanigawa T, Watanabe K, Machida H, Okazaki H, Yamagami H, Watanabe K, Tominaga K, Watanabe T, Fujiwara Y, Arakawa T.
    Am J Gastroenterol; 2012 Aug 18; 107(8):1266-8. PubMed ID: 22859008
    [No Abstract] [Full Text] [Related]

  • 10. Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome.
    Ciccia F, Giardina A, Rizzo A, Guggino G, Cipriani P, Carubbi F, Giacomelli R, Triolo G.
    Ann Rheum Dis; 2013 May 18; 72(5):782-3. PubMed ID: 23264342
    [No Abstract] [Full Text] [Related]

  • 11. Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis.
    St Clair EW, Levesque MC, Prak ET, Vivino FB, Alappatt CJ, Spychala ME, Wedgwood J, McNamara J, Moser Sivils KL, Fisher L, Cohen P, Autoimmunity Centers of Excellence.
    Arthritis Rheum; 2013 Apr 18; 65(4):1097-106. PubMed ID: 23334994
    [Abstract] [Full Text] [Related]

  • 12. Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjogren's syndrome.
    Pollard RP, Abdulahad WH, Bootsma H, Meiners PM, Spijkervet FK, Huitema MG, Burgerhof JG, Vissink A, Kroese FG.
    Ann Rheum Dis; 2013 Dec 18; 72(12):2048-50. PubMed ID: 23864239
    [No Abstract] [Full Text] [Related]

  • 13. Treatment approaches in primary Sjogren syndrome.
    Vissink A, Kallenberg CG, Bootsma H.
    JAMA; 2010 Nov 10; 304(18):2015-6; author reply 2016. PubMed ID: 21063008
    [No Abstract] [Full Text] [Related]

  • 14. Sustained response to rituximab in a patient with Sjögren´s syndrome and severe refractory polyneuropathy.
    Pertovaara M, Korpela M.
    Clin Exp Rheumatol; 2012 Nov 10; 30(5):808; author reply 809. PubMed ID: 22992382
    [No Abstract] [Full Text] [Related]

  • 15. Maintenance of rituximab treatment in a patient with primary Sjögren's syndrome.
    Lehner GF, Brunner-Palka M, Rettenbacher T, Schmidauer R, Herold M.
    Rheumatology (Oxford); 2014 Jul 10; 53(7):1349-50. PubMed ID: 24446469
    [No Abstract] [Full Text] [Related]

  • 16. [Efficiency of rituximab in an unusual form of primary Sjögren's syndrome: a case report].
    Mrabet D, Meddeb N, Sahli H, Saadi F, Chéour E, Elleuch M, Sellami S.
    Therapie; 2010 Jul 10; 65(6):581-3. PubMed ID: 23189757
    [No Abstract] [Full Text] [Related]

  • 17. Rituximab in primary Sjögren's syndrome: a ten-year journey.
    Carubbi F, Alunno A, Cipriani P, Bartoloni E, Ciccia F, Triolo G, Gerli R, Giacomelli R.
    Lupus; 2014 Nov 10; 23(13):1337-49. PubMed ID: 25096066
    [Abstract] [Full Text] [Related]

  • 18. Dramatic reversal of lymphocytic interstitial pneumonitis in Sjögren's syndrome with rituximab.
    Swartz MA, Vivino FB.
    J Clin Rheumatol; 2011 Dec 10; 17(8):454. PubMed ID: 22126805
    [No Abstract] [Full Text] [Related]

  • 19. Rituximab and lupus interstitial lung disease: friend or foe?
    Efthimiou P, Kukar M, Hersh A.
    Int J Rheum Dis; 2011 Feb 10; 14(1):e3-4. PubMed ID: 21303472
    [No Abstract] [Full Text] [Related]

  • 20. [The treatment of secondary Sjogren syndrome].
    Vultur F, Borda A, Horvath K, Máté-István I.
    Oftalmologia; 2010 Feb 10; 54(4):49-54. PubMed ID: 21516863
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.